Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance of each kit in discriminating SARS-CoV-2 infection.

Article Snippet: For the GenScript cPass sVNT kit, dilution was not conducted because the method represents the result of the inhibition ratio calculated from the optical density measured, which does not necessarily linearly correlate with the titer of the antibodies.

Techniques: Infection

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Analytical performance for representativeness of neutralizing activity using the pre-defined cut-off values of each immunoassay kit.

Article Snippet: For the GenScript cPass sVNT kit, dilution was not conducted because the method represents the result of the inhibition ratio calculated from the optical density measured, which does not necessarily linearly correlate with the titer of the antibodies.

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Titer correlation of the analytical performance of the prediction of neutralizing activity using newly calculated cut-off values determined using Youden’s index.

Article Snippet: For the GenScript cPass sVNT kit, dilution was not conducted because the method represents the result of the inhibition ratio calculated from the optical density measured, which does not necessarily linearly correlate with the titer of the antibodies.

Techniques: Activity Assay

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Serial kinetics of antibody titers measured with each method: (A) PRNT ND50, (B.) GenScript cPass sVNT, (C) Roche Elecsys Anti-SARS-CoV-2, (D) Roche Elecsys Anti-SARS-CoV2 S, and (E) Abbott AdviseDx SARS-CoV2 IgG II.

Article Snippet: For the GenScript cPass sVNT kit, dilution was not conducted because the method represents the result of the inhibition ratio calculated from the optical density measured, which does not necessarily linearly correlate with the titer of the antibodies.

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Antibody titers by timeline.

Article Snippet: For the GenScript cPass sVNT kit, dilution was not conducted because the method represents the result of the inhibition ratio calculated from the optical density measured, which does not necessarily linearly correlate with the titer of the antibodies.

Techniques:

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays

doi: 10.3389/fcimb.2022.822599

Figure Lengend Snippet: Scatter plot and Pearson’s correlation for each method grouped with acute/convalescent phase. (A) GenScript cPass sVNT, (B) Roche Elecsys Anti-SARS-CoV-2, (C) Roche Elecsys Anti-SARS-CoV2 S, and (D) Abbott AdviseDx SARS-CoV2 IgG II were compared with PRNT, respectively. Each colored line depicts the linear regression model and the surrounding grey-colored area represents the 95% confidence interval.

Article Snippet: For the GenScript cPass sVNT kit, dilution was not conducted because the method represents the result of the inhibition ratio calculated from the optical density measured, which does not necessarily linearly correlate with the titer of the antibodies.

Techniques:

Journal: Kidney360

Article Title: Clinical Course of SARS-CoV-2 Infection in Adults with ESKD Receiving Outpatient Hemodialysis

doi: 10.34067/KID.0004372021

Figure Lengend Snippet: Longitudinal results from end-stage renal disease (ESRD) participants on maintenance dialysis. (A) Longitudinal results including RT-PCR, viral culture, symptom onset, SARS-CoV-2–specific antibodies, and positive neutralizing antibodies from participants with ESKD on maintenance dialysis with SARS-CoV-2 infection (N=15). (B) Longitudinal results including RT-PCR, viral cultures, symptom onset, and positive and negative symptoms from participants with ESKD on maintenance dialysis with SARS-CoV-2 infection (N=15). Thirteen participants completed the assessment. Participants D and K withdrew before the end of the assessment. Day of diagnosis is displayed as day 0 on the x axis and represents the day of diagnosis recorded in the facility’s medical record (either RT-PCR or antigen test). For each visit, a composite RT-PCR result was determined on the basis of available RT-PCR results from all specimens collected at each visit (oropharyngeal, anterior nasal, and saliva). We defined RT-PCR positivity as having any of the three specimens RT-PCR positive, inconclusive if there was no positive RT-PCR but at least one inconclusive test, and negative if all specimens were negative by RT-PCR. Antibody to the SARS-CoV-2 spike protein was positive if ≥100. Positive neutralization was defined as ≥70% of inhibition using a Genscript cPass Surrogate Neutralization Kit. Group 1: diagnosis of SARS-CoV-2 infection was ≤5 days before enrollment. Group 2: diagnosis of SARS-CoV-2 infection was 6–15 days before enrollment. Group 3: diagnosis of SARS-CoV-2 infection was >15 days before enrollment and evidence of recent RT-PCR positivity (i.e., positive RT-PCR ≤5 days of enrollment). Symptomatic was defined as reporting any symptoms from the coronavirus disease 2019 symptoms list (included in Table 1) during a particular visit. Participant A had rheumatoid arthritis and was taking 5 mg/d prednisone. Participants D and H had a history of kidney allograft failure and were taking immunosuppressive medications. Participant L received convalescent plasma and Ig in the first 2 days after diagnosis. The remaining patients had no immunosuppressive conditions. ID, identifier; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Article Snippet: Positive neutralization was defined as ≥70% of inhibition using a Genscript cPass Surrogate Neutralization Kit.

Techniques: Reverse Transcription Polymerase Chain Reaction, Infection, Biomarker Discovery, Neutralization, Inhibition, Medications, Clinical Proteomics

Journal: Kidney360

Article Title: Clinical Course of SARS-CoV-2 Infection in Adults with ESKD Receiving Outpatient Hemodialysis

doi: 10.34067/KID.0004372021

Figure Lengend Snippet: Detection of SARS-CoV-2 neutralizing antibodies among patients with ESKD on maintenance dialysis with SARS-CoV-2 infection (N=15) since diagnosis. Surrogate neutralization antibodies were measured using the Genscript cPass Surrogate Neutralization Kit. The results are presented as percentages and represent the percent that particular serum specimen blocked the interaction between the SARs-CoV-2 receptor binding domain and the angiotensin-converting enzyme 2 cellular receptor. The higher the number, the more surrogate neutralization activity; ≥70% (dashed line) was considered positive. Participant A had rheumatoid arthritis and was taking 5 mg/d prednisone. Participants D and H had a history of kidney allograft failure and were taking immunosuppressive medications. Participant L received convalescent plasma and Ig in the first 2 days after diagnosis. Participants D and K withdrew before the end of the assessment. Participants D and E did not have documented seroconversion. ID, identifier.

Article Snippet: Positive neutralization was defined as ≥70% of inhibition using a Genscript cPass Surrogate Neutralization Kit.

Techniques: Infection, Biomarker Discovery, Neutralization, Binding Assay, Activity Assay, Medications, Clinical Proteomics